Butyrate-induced proapoptotic and antiangiogenic pathways in EAT cells require activation of CAD and downregulation of VEGF

Biochemical and Biophysical Research Communications

Volumn 335, Issue 4, 2005, Pages 993-1001

  Belakavadi, Madesh ^a   Prabhakar, B T ^a   Salimath, Bharathi P ^a  

^a UNIVERSITY OF MYSORE   (India)

Author keywords

Antiangiogenesis; Apoptosis; Butyrate; CAD; CD31; DNase II; VEGF

Indexed keywords

BUTYRIC ACID; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CD31 ANTIGEN; DEOXYRIBONUCLEASE; DNA FRAGMENT; LIPOCORTIN 5; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EHRLICH ASCITES TUMOR CELL; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PERITONEUM; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY MECHANISM; STAINING;

ANIMALS; APOPTOSIS; BUTYRIC ACID; CARCINOMA, EHRLICH TUMOR; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYRIBONUCLEASES; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24044440958     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.07.172     Document Type: Article

References (47)

1. J. Folkman Tumor angiogenesis: therapeutic implications New Engl. J. Med. 285 1971 1182 1186
2. K.A. Houck, N. Ferrara, J. Winer, G. Cachianes, B. Li, and D.W. Leung The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA Mol. Endocrinol. 5 1991 1806 1814
3. J.L. Arbiser, N. Klauber, R. Rohan, R. van Leeuwen, M.T. Huang, C. Fisher, E. Flynn, and H.R. Byers Curcumin is an in vivo inhibitor of angiogenesis Mol. Med. 4 1998 376 383
4. A.E. Gururaj, M. Belakavadi, D.A. Venkatesh, D. Marme, and B.P. Salimath Molecular mechanisms of antiangiogenic effect of curcumin Biochem. Biophys. Res. Commun. 297 2002 934 942
5. J.K. Min, K.Y. Han, E.C. Kim, Y.M. Kim, S.W. Lee, O.H. Kim, K.W. Kim, Y.S. Gho, and Y.G. Kwon Capsaicin inhibits in vitro and in vivo angiogenesis Cancer Res. 64 2004 644 651
6. Y.J. You, N.H. Nam, Y. Kim, K.H. Bae, and B.Z. Ahn Antiangiogenic activity of lupeol from Bombax ceiba Phytother. Res. 17 2003 341 344
7. K.J. Kim, B. Li, J. Winer, M. Aranini, N. Gillett, H.S. Phillips, and N. Ferrara Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumor growth in vivo Nature 362 1993 841 844
8. G. Gasparini, and A.L. Harris Clinical Implications of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool J. Clin. Oncol. 13 1995 30 37
9. B. Stoelcker, B. Echtenacher, H.A. Weich, H. Sztajer, D.J. Hcklin, and D.N. Mannel VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence J. Interferon Cytokine Res. 20 2000 511 517
10. S. Mesiano, N. Ferrara, and R.B. Jaffe Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization Am. J. Pathol. 153 1998 1249 1256
11. A. Yukita, M. Asano, T. Okamoto, S. Mizutani, and H. Suzuki Suppression of ascites formation and re-accumulation associated with human ovarian cancer by anti-VPF monoclonal antibody in vivo Anticancer Res. 20 2000 445 454
12. N.W. Gale, and G.D. Yancopoulos Growth factors acting via endothelial cell specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development Genes Dev. 13 1999 1055 1066
13. C. Giardina, and M.S. Inan Nonsteroidal anti-inflammatory drugs, short chain fatty acids and reactive metabolism in human colorectal cancer cells Biochim. Biophys. Acta 1401 1998 277 288
14. A. Patnaik, K.E.K. Rowinsky, A.M.A. Villalona, L.A. Hammond, C.D. Britten, L.L. Siu, A. Goetz, S.A. Felton, S. Burton, F.H. Valone, and S.G. Eckhardt A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies Clin. Cancer Res. 8 2002 2142 2148
15. J.Y. Douillard, J. Bennaouna, F. Vavasseur, R. Deporte-Fety, P. Thomare, F. Giacalone, and K. Meflah Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer Cancer Immunol. Immunother. 49 2000 56 61
16. A. Hague, A.M. Manning, K.A. Hanlon, L.I. Huschtscha, D. Hart, and C. Paraskeva Sodium butyrate induces apoptosis in human colonic tumor cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer Int. J. Cancer 55 1993 498 505
17. B.G. Heerdt, M.A. Houston, and L.H. Augenlicht Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines Cancer Res. 54 1994 3288 3293
18. B. Singh, A.P. Halestrap, and C. Paraskeva Butyrate can act as a stimulator of growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources Carcinogenesis 18 1997 12655 12670
19. J.A. Barnard, and G. Warwick Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells Cell Growth Differ. 4 1993 495 501
20. F.M. Ruemmele, S. Dionne, I. Qureshi, D.S. Sarma, E. Levy, and E.G. Seidman Butyrate mediates Caco-2 cell apoptosis via up-regulation of pro-apoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP) Cell Growth Differ. 6 1999 729 735
21. V. Medina, B. Edmonds, G.P. Young, R. James, S. Appleton, and P.D. Zalewski Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway Cancer Res. 57 1997 3697 3707
22. F. Chai, A. Evdokiou, G.P. Young, and P.D. Zalewski Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate Carcinogenesis 1 2000 7 14
23. H. Kobayashi, E.M. Tan, and S.E. Fleming Sodium butyrate inhibits cell growth and stimulates p21WAF1/CIP1 protein in human colonic adenocarcinoma cells independently of p53 status Nutr. Cancer 46 2003 202 211
24. P. Rocchi, R. Tonelli, C. Camerin, S. Purgato, R. Fronza, F. Bianucci, F. Guerra, A. Pession, and A.M. Ferreri p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells Oncol. Rep. 6 2005 1139 1144
25. V. Chopin, R.A. Toillon, N. Jouy, and X. Le Bourhis Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells Br. J. Pharmacol. 135 2002 79 86
26. P.A. Marks, V.M. Richon, and R.A. Rifkind Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 92 2000 1210 1216
27. L. Yin, G. Laevsky, and C. Giardina Butyrate suppression of colonocyte NF-kB activation and cellular proteosome activity J. Biol. Chem. 276 2001 44641 44646
28. H. Sawa, H. Murakami, Y. Ohshima, M. Murakami, I. Yamazaki, Y. Tamura, T. Mima, A. Satone, W. Ide, I. Hashimoto, and H. Kamada Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells Brain Tumor Pathol. 19 2002 77 81
29. C. Pellizzaro, D. Coradini, and M.G. Daidone Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29 Carcinogenesis 23 2002 735 740
30. H. Ogawa, P. Rafiee, P.J. Fisher, N.A. Johnson, M.F. Otterson, and D.G. Binikon Sodium butyrate inhibits angiogenesis of human intestinal microvascular endothelial cells through COX-2 inhibition FEBS Lett. 554 2003 88 94
31. A.E. Gururaj, M. Belakavadi, and B.P. Salimath Antiangiogenic effects of butyric acid involve inhibition of VEGF/KDR gene expression and endothelial cell proliferation Mol. Cell. Biochem. 243 2003 107 112
32. D. Zgouras, A. Wachtershauser, D. Frings, and J. Stein Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1α nuclear translocation Biochem. Biophys. Res. Commun. 300 2003 832 838
33. G. Srinivas, R. John Anto, P. Srinivas, S. Vidhyalakshmi, V. Priya Senan, and D. Karunagaran Emodin induces apoptosis of human cervical cancer cells through poly (ADP-ribose) polymerase cleavage and activation of caspase-9 Eur. J. Pharmacol. 473 2003 117 125
34. C.J. Stein, and G. Hansen Mannose induces an endonuclease responsible for DNA laddering in plant cells Plant Physiol. 121 1999 71 79
35. Y. Nakagami, M. Ito, T. Hara, T. Inoue, and S. Matsubara Nuclear translocation of DNase II and acid phosphatase during radiation-induced apoptosis in HL60 cells Acta Oncol. 42 2003 227 236
36. I.K. Wang, S.Y. Lin-Shiau, and J.K. Lin Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells Pharmacol. Toxicol. 86 2000 83 91
37. M.A. Barry, and A. Eastman Identification of deoxyribonuclease II as an endonuclease involved in apoptosis Arch Biochem. Biophys. 300 1993 440 450
38. C.J. Evans, and R.J. Aguilera DNase II: genes, enzymes and function Gene 322 2003 1 15
39. J.H. Dulaney, and O. Touster Isolation of deoxyribonuclease II of rat live lysozomes J. Biol. Chem. 247 1972 1424 1432
40. J. Kruh, N. Defer, and L. Tichonicky Effects of butyrate on cell proliferation and gene expression J.H. Cummings J.L. Rombeau T. Sakata Physiological and Clinical Aspects of Short Chain Fatty Acids 1996 Cambridge University Press Cambridge, England
41. H. Sakahira, M. Enari, and S. Nagata Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis Nature 391 1998 96 99
42. P. Widlak The DEF40/CAD endonuclease and its role in apoptosis Acta Biochim. Pol. 47 2000 1037 1044
43. S. Nagata DNA degradation in development and programmed cell death Annu. Rev. Immunol. 23 2005 853 875
44. K.D. Miller, C.J. Sweeney, and G.W. Sledge Redefining the target: chemotherapeutics as antiangiogenics J. Clin. Oncol. 19 2001 1195 1206
45. M. Schirner Antiangiogenic chemotherapeutic agents Cancer Metastasis Rev. 19 2000 67 73
46. P. Albertsson, B. Lennenaes, and K. Norrby Chemotherapy and antiangiogenesis, drug-specific effects on microvessel sprouting APMIS 111 2003 995 1003
47. M.K. Clements, C.B. Jones, M. Cumming, and S.S. Daoud Antiangiogenic potential of camptothecin and topotecan Cancer Chemother. Pharmacol. 44 1999 411 416